生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 06-23 16:00:00

4,410.914

+7.880

+0.18%

最高4,559.563	最低4,354.550	成交量2.75亿
今开4,403.033	昨收4,403.033	日振幅4.66%
总市值0.00	流通市值0.00	总股本0.00
成交额61.74亿	换手率--	流通股本0.00
市净率4.975436	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":4410.9136,"timestamp":1782202096840,"preClose":4403.033,"halted":0,"volume":275253630,"delay":0,"changeRate":0.00179,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":7.880371,"latestTime":"06-23 16:00:00","open":4403.033,"high":4559.563,"low":4354.55,"amount":6173841093.5,"amplitude":0.046562,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782264600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1782178200000,1782187200000],[1782190800000,1782201600000]],"pbRate":4.975436,"peRate":-300.748474,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2645385867","title":"“回购潮”彰显医药行业三重价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2645385867","media":"证券日报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645385867?lang=zh_cn&edition=full","pubTime":"2026-06-24 00:20","pubTimestamp":1782231600,"startTime":"0","endTime":"0","summary":"近来，医药板块迎来一波“回购潮”。A股和H股超百家医药上市公司发布回购计划或进展，其中，创新药企成为核心力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243780119994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645083082","title":"药捷安康大跌60%：市值降至46亿港元 无收入却曾市值超千亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2645083082","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645083082?lang=zh_cn&edition=full","pubTime":"2026-06-23 23:22","pubTimestamp":1782228146,"startTime":"0","endTime":"0","summary":"港股有这样一家神奇的企业，无任何营收，却曾市值超过2000亿港元，如今，被打回原形，市值跌至不足50亿港元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785372985016268134583.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785372985016268134583.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34120/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645837657","title":"3个月50倍大牛股“崩”了，今天暴跌近60%，2500亿市值只剩零头","url":"https://stock-news.laohu8.com/highlight/detail?id=2645837657","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645837657?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:30","pubTimestamp":1782225001,"startTime":"0","endTime":"0","summary":"2026年6月23日，港股18A创新药企药捷安康-B股价大跌，股价早盘大幅跳空低开后持续俯冲，最终收跌59.71%，每股报11.25港元，一举跌破13.15港元的IPO发行价，创下上市以来历史新低。这家股价曾经在三个月大涨超50倍的网红创新药企，市值已从最高2500亿港元跌至47亿港元，市值缩水98%。2026年6月22日，公司12个月大额限售股正式解禁，覆盖控股股东、全部上市前机构投资者，解禁股份体量是现有流通盘的数十倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://finance.ifeng.com/c/8uCSNq902yo","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8uCSNq902yo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK1161","EWH","02617","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832975","title":"亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832975","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645832975?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:22","pubTimestamp":1782224535,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，亚虹医药报收于10.04元，较前一交易日上涨0.5%，最新总市值为57.45亿元。近日，江苏亚虹医药科技股份有限公司发布首次公开发行部分限售股上市流通公告。公告显示，本次解除限售股份数量为135,484,537股，占公司当前总股本的23.68%。本次限售股将于2026年7月1日上市流通，涉及股东2名，分别为PAN KE和ZHUANG CHENGFENG JOHN；解除限售后剩余限售股数量为0。上述股东均严格履行了限售承诺，保荐机构中信证券对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1515","688176","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383250","title":"诺诚健华（688428）披露2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市，6月23日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383250","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645383250?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:14","pubTimestamp":1782224091,"startTime":"0","endTime":"0","summary":"近日，诺诚健华医药有限公司发布《关于2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告》。公告显示，公司完成2024年科创板限制性股票激励计划首次授予部分第一个归属期的股份登记，本次归属股票数量为2,418,300股，来源为公司向激励对象定向发行人民币普通股，归属人数为74人，其中包含董事、高级管理人员及核心技术人等。本次归属新增股份已于2026年6月22日完成登记，上市流通日期为2026年6月26日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","688428","BK0239","159982","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645834956","title":"宝发控股(08532)：附属清盘呈请聆讯重新安排至6月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2645834956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645834956?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:53","pubTimestamp":1782222839,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝发控股(08532)发布公告，内容有关马健铮先生就公司全资附属公司宝发建筑工程有限公司提交的清盘呈请。公司现提供最新情况，呈请人于原定聆讯日期申请押后聆讯，法庭已将聆讯重新安排至2026年6月24日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1158","08532","08592","BK1148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836211","title":"成大生物（688739）新增【创新药】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836211","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645836211?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:30","pubTimestamp":1782217824,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，6月23日成大生物新增概念。成大生物主营业务：人用疫苗的研发、生产和销售。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300039466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","BK0239","06978","688739","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645783632","title":"维升药业-B(02561)6月23日斥资约7.68万港元回购4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645783632","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645783632?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:13","pubTimestamp":1782216790,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月23日该公司斥资约7.68万港元回购4000股，回购价格为每股19.17至19.24港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645350838","title":"港股创新药板块估值修复机遇可期，关注港股通创新药ETF易方达（159316）中长期配置价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2645350838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645350838?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:42","pubTimestamp":1782211331,"startTime":"0","endTime":"0","summary":"6月23日，医药板块逆势走强，截至收盘，恒生港股通创新药指数上涨0.6%，中证港股通医药卫生综合指数上涨0.4%，中证创新药产业指数上涨1.4%，中证生物科技主题指数上涨0.6%，沪深300医药卫生指数下跌0.1%。从产业基本面来看，港股聚集了大量未盈利但管线价值突出的创新药标的，在ADC、双抗、细胞治疗等前沿领域具备全球竞争力。有观点认为，随着国产创新药海外授权交易持续活跃、港股创新药企业逐步进入盈利释放阶段，港股创新药板块在经历前期调整后，中长期配置价值逐步显现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026062300032933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["516080","159992","BK1574","159316","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880777","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645880777?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:37","pubTimestamp":1782211020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请获得批准。6MW5311是基于公司T Cell Engager(TCE)技术平台开发的一款靶向LILRB4/CD3的双特异性抗体，拟开发适应症为：血液瘤(AML、CMML以及MM)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK1161","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887094","title":"中慧生物-B(02627)：mRNA猴痘疫苗获中国药审中心的IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887094","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645887094?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:10","pubTimestamp":1782209455,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，继本集团获美国食品药物监督管理局批准其于美国提交的临床研究用新药申请后，国家药品监督管理局药品审评中心已于2026年6月21日批准本集团自主研发的mRNA猴痘疫苗候选产品的IND申请。猴痘由猴痘病毒引发，而猴痘病毒是痘病毒科正痘病毒属的一员。其为全球首个同时获FDA及中国药审中心批准IND申请的mRNA猴痘疫苗候选产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK1161","IND","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146063254","title":"歌礼制药宣布其用于治疗肥胖症的月度皮下注射GLP-1R/GIPR双肽激动剂ASC35获美国FDA批准进行I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1146063254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146063254?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:10","pubTimestamp":1782209436,"startTime":"0","endTime":"0","summary":"歌礼制药宣布，其用于治疗肥胖症的月度皮下注射GLP-1R/GIPR双肽激动剂ASC35，已获得美国食品药品监督管理局的临床试验申请批准，将进入I期研究阶段。该候选药物ASC35是一种创新的长效双激动剂，旨在同时靶向胰高血糖素样肽-1受体和葡萄糖依赖性促胰岛素多肽受体。与目前市场上常见的每日或每周给药方案不同，ASC35采用了每月一次的皮下注射给药方式，有望为患者提供更便捷的治疗选择，并可能改善用药依从性。此次IND获批标志着该药物研发进程中的一个重要里程碑，公司计划尽快启动相关的临床研究以评估其安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645872788","title":"歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645872788","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645872788?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:04","pubTimestamp":1782209049,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，近期已获得美国食品药品监督管理局对其ASC35的I期研究的新药临床试验批准。ASC35是一款有望成为同类最佳、每月一次皮下注射的GLP-1受体/GIP受体 双靶点激动剂多肽，用于治疗肥胖症。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4160","BK4588","GLP","LABU","BK1515","IND","BK1574","GIPR","BK4590","BK1191","01477","BK4585","BK4144","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645564887","title":"6月23日君实生物现1笔大宗交易 机构净买入1905.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645564887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645564887?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:52","pubTimestamp":1782208366,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日君实生物发生大宗交易，交易数据如下：大宗交易成交价格30.24元，相对当日收盘价折价0.62%，成交63万股，成交金额1905.12万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。近三个月该股共发生11笔大宗交易，合计成交7.21万手，折价成交11笔。截至2026年6月23日收盘，君实生物报收于30.43元，上涨0.93%，换手率2.35%，成交量18.0万手，成交额5.52亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300031111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1583","BK1161","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112474381","title":"Organon加拿大与复宏汉霖推出Prolia与Xgeva生物类似药Bildyos®及Tuzemty®，扩大地舒单抗治疗可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1112474381","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112474381?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:31","pubTimestamp":1782207107,"startTime":"0","endTime":"0","summary":"Organon加拿大与复宏汉霖通过推出Prolia和Xgeva的生物类似药——Bildyos®（地舒单抗注射液）与Tuzemty®（地舒单抗注射液），显著扩大了地舒单抗治疗的可及性。这两款新药的上市，为患者提供了更多治疗选择，并有望通过竞争促进药品可负担性的提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","02696","HK0000306701.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645848568","title":"亿胜生物科技(01061)6月23日斥资31.73万港元回购12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645848568","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645848568?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:55","pubTimestamp":1782204942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，于2026年6月23日，该公司斥资31.73万港元回购12万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01061"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645288123","title":"6月23日健民集团涨6.21%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645288123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645288123?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:46","pubTimestamp":1782204365,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日健民集团涨6.21%，收盘报28.92元，换手率4.31%，成交量6.61万手，成交额1.88亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-33.22%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","159938","BK1515","600976","BK0209","BK0250","BK0188","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645912886","title":"A股主要指数全线调整，但超半数个股飘红，创业板指跌超3.8%；创新药概念股大涨，银行、券商上涨，贵金属板块下挫｜A股收盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2645912886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645912886?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:29","pubTimestamp":1782199777,"startTime":"0","endTime":"0","summary":"6月23日，市场震荡调整，创业板指、深成指低开低走。四大股指今日集体收跌，上证指数报收4106.25点，跌1.37%，深成指报收15854.2点，跌3.17%，创业板指报收4192.19点，跌3.84%，科创综指报收2278.73点，跌1.31%。沪深两市成交额3.47万亿，较上一个交易日缩量2961亿。全市场2763只个股上涨，2642只个股下跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779675811.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779675811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","161121","BK1574","399006","399300","159992","159982","07234","399001","03147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645885273","title":"沪指跌1.37%，创指跌3.84%：医药板块逆势走强，两市成交3.4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645885273","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645885273?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:17","pubTimestamp":1782199020,"startTime":"0","endTime":"0","summary":"　　A股三大股指6月23日集体低开。午后两市震荡下行，跌幅明显扩大，创指更是一度跌4.59%。医药、银行板块逆势走强。　　至收盘，上证综指跌1.37%，报4106.25点；深证成指跌3.17%，报15854.2点；创业板指跌3.84%，报4192.19点。　　Wind统计显示，两市及北交所共2763只股票上涨，2642只股票下跌，平盘有120只股票。　　沪深两市成交总额34407亿元，较前一交易日的37372亿元减少2965亿元。其中，沪市成交15945亿元，比上一交易日17040亿元减少1095亿元，深市成交18462亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-06-23/doc-iniekqur9741873.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-23/doc-iniekqur9741873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399006","000905.SH","159967","512510","BK1574","515890","09939","000300.SH","512880","000001.SH","159938","BK1515","510880","510300","000688.SH","BK1161","399001","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645288556","title":"百洋医药：锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2645288556","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645288556?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:00","pubTimestamp":1782198045,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，锝[99mTc]佩昔瑞特加肽注射液自上市以来，是否医院已经开出第一单了，患者使用效果如何？百洋医药回复：投资者您好，锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药，全球首个用于SPECT显像诊断的广谱肿瘤显像药物。目前公司正按照经营计划有序进行商业化推广工作，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300020087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK1161","301015","159992","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0886},{"period":"3month","weight":-0.0789},{"period":"6month","weight":-0.0962},{"period":"1year","weight":-0.0149},{"period":"ytd","weight":-0.0895}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}